Boston Scientific to Acquire Apollo Endosurgery for $615 Million

Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B

March 3, 2021

Medical Devices

Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.

Boston Scientific Acquires Axonics, Inc.

November 15, 2024

Medical Devices

Boston Scientific agreed to acquire Axonics, a medical technology company focused on urinary and bowel dysfunction, for $71 per share in cash, valuing the equity at approximately $3.7 billion. The boards approved the transaction, which was expected to close in the first half of 2024, and Boston Scientific later announced the acquisition closed on November 15, 2024.

Biogen to Acquire Apellis Pharmaceuticals for Approximately $5.6 Billion

March 31, 2026

Pharmaceuticals

Biogen entered into a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash. The deal is intended to expand Biogen’s presence in immunology and rare disease, adding commercial-stage therapies SYFOVRE and EMPAVELI and supporting growth initiatives in nephrology.

Boston Scientific Acquires Silk Road Medical for $27.50 per Share

June 18, 2024

Medical Devices

Boston Scientific Corporation agreed to acquire Silk Road Medical, Inc. for $27.50 per share in an all-cash transaction valuing Silk Road's equity at approximately $1.26 billion. The acquisition brings Silk Road's TransCarotid Artery Revascularization (TCAR) platform into Boston Scientific's vascular portfolio to expand treatment options for carotid artery disease and strengthen the company's vascular technology offerings.

Boston Scientific Agrees to Acquire Bolt Medical

January 8, 2025

Medical Devices

Boston Scientific Corporation entered into a definitive agreement to acquire Bolt Medical, Inc., developer of an intravascular lithotripsy (IVL) laser-based platform for treating calcified coronary and peripheral artery disease. The deal includes an upfront payment of about $443 million for the 74% stake Boston Scientific does not already own, plus up to $221 million tied to regulatory milestones.

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.